bioMerieux announced the launch of its immunoassay endocrinology offer for equine health, consisting of VIDAS Equine INSULIN and VIDAS Equine ACTH. By providing fast and accurate test results of insulin levels in approximately 20 minutes, VIDAS Equine INSULin will help with the diagnosis and effective management of Equine Metabolic Syndrome (EMS), commonly associated with insulin dysregulation in horses. VIDAS Equine ACTH provides dysregulation level testing of the adrenocorticotropic (ACTH) hormone related to the development of Equine Cushing's Disease (correctly known as Pituitary Pars Intermedia Dysfunction - PPID) in just about 45 minutes.
Between 18%-27% of horses over 15 years old show symptoms related to Cushing's or insulin dysregulation. Those common equine endocrine disorders can increase risk for complication, especially chronic laminitis2. Laboratory standard hormone tests will become available in the UK at the Point of Care using bioMerieux's VIDAS KUBE immunoanalyser, marking the first equine-focused testing platform to launch with this capability.
After the launch last June of VETFIRETM, a cutting-edge PCR test for detecting respiratory infections in horses, bioMerieux continues to transfer its expertise in the human testing sector to veterinary practice, reducing wait times for results and enabling faster clinical decisions with the combined diagnostic power of the two VIDAS Equine endocrinology tests. With this scientifically precise, on-demand technological innovation, bioMerieux brings to veterinary medicine its 60+ years of expertise in clinical diagnostics and continues to expand its high-quality offering to meet the needs of the fast-moving veterinary and equine sectors. The two new tests will initially be available in the United Kingdom and France, with international rollout planned in the coming months.
